<?xml version="1.0" encoding="UTF-8"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-10-19T03:29:51Z</responseDate><request verb="GetRecord" identifier="oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/10458" metadataPrefix="oai_dc">https://ebyu-rdlopen.rawdatalibrary.net/oai/request</request><GetRecord><record><header><identifier>oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/10458</identifier><datestamp>2026-10-18T21:13:07Z</datestamp><setSpec>openaire</setSpec><setSpec>driver</setSpec><setSpec>com_ebyu_10000</setSpec><setSpec>col_ebyu_10001</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:title>Herniarin mitigates inflammation, oxidative stress, and apoptosis in experimental serous otitis media via NRF2/HO-1 and NLRP3/Caspase-1 pathways</dc:title><dc:creator>Kozan, Günay</dc:creator><dc:creator>Erbaş, Elif</dc:creator><dc:creator>Üstündağ, Hilal</dc:creator><dc:creator>Kara, Adem</dc:creator><dc:subject>Coumarin</dc:subject><dc:subject>Herniarin</dc:subject><dc:subject>Inflammation</dc:subject><dc:subject>NLRP3 inflammasome</dc:subject><dc:subject>NRF2/HO-1</dc:subject><dc:subject>Otitis media</dc:subject><dc:subject>Oxidative stress</dc:subject><dc:subject>Animals</dc:subject><dc:subject>Anti-Inflammatory Agents</dc:subject><dc:subject>Antioxidants</dc:subject><dc:subject>Apoptosis</dc:subject><dc:subject>Caspase 1</dc:subject><dc:subject>Coumarins</dc:subject><dc:subject>Dexamethasone</dc:subject><dc:subject>Disease Models, Animal</dc:subject><dc:subject>Glutathione</dc:subject><dc:subject>Heme Oxygenase (Decyclizing)</dc:subject><dc:subject>Heme Oxygenase-1</dc:subject><dc:subject>Interleukin-18</dc:subject><dc:subject>Interleukin-1beta</dc:subject><dc:subject>Male</dc:subject><dc:subject>Malondialdehyde</dc:subject><dc:subject>NF-E2-Related Factor 2</dc:subject><dc:subject>NLR Family, Pyrin Domain-Containing 3 Protein</dc:subject><dc:subject>Otitis Media with Effusion</dc:subject><dc:subject>Proto-Oncogene Proteins c-bcl-2</dc:subject><dc:subject>Rats</dc:subject><dc:subject>Rats, Wistar</dc:subject><dc:subject>Signal Transduction</dc:subject><dc:subject>Superoxide Dismutase</dc:subject><dc:description>Objective Serous otitis media (SOM) is a prevalent inflammatory condition of the middle ear. Herniarin (7-methoxycoumarin) is a coumarin derivative with anti-inflammatory and antioxidant properties. This study aimed to investigate the therapeutic potential of herniarin against experimentally induced SOM in rats, focusing on the NRF2/HO-1 and NLRP3/Caspase-1 pathways. Methods Thirty six adult male Wistar rats were allocated into six groups (n = 6): Control, Herniarin 200 mg/kg, Otitis, Otitis + Herniarin 100 mg/kg, Otitis + Herniarin 200 mg/kg, and Otitis + Dexamethasone. SOM was induced by established experimental protocols, and treatments were administered for seven consecutive days. Serum cytokines (IL-1β, TNF-α, IL-18), oxidative stress markers (GSH, SOD, MDA), histopathology, RT-qPCR, and Western blot analyses were performed. Results Serum levels of IL-1β, TNF-α, and IL-18 were significantly elevated in the otitis group compared with controls (p &lt; 0.0001) and were markedly attenuated by herniarin and dexamethasone. Herniarin restored depleted GSH and SOD levels while reducing elevated MDA concentrations. Histopathological examination demonstrated dose-dependent attenuation of inflammatory cell infiltration, hemorrhage, and tympanic membrane damage. RT-qPCR showed that herniarin suppressed the upregulation of HO-1, NRF2, NF-κB, and Caspase-3 gene expression induced by otitis, while restoring Bcl-2 expression toward control levels. Western blot confirmed that herniarin reduced the expression of NLRP3, Caspase-1, and Caspase-3, and of NF-κB, while increasing Bcl-2 levels. Conclusion Herniarin exerts protective effects against experimental SOM by modulating the NRF2/HO-1 antioxidant defense system and suppressing NLRP3 inflammasome-mediated inflammation and apoptosis, suggesting its potential as a therapeutic candidate for otitis media. © 2026 Oto-Rhino-Laryngological Society of Japan Inc.</dc:description><dc:publisher>Elsevier Ireland Ltd</dc:publisher><dc:date>2026</dc:date><dc:type>Article</dc:type><dc:identifier>https://rdlopen.rawdatalibrary.net/r/ebyu/10458</dc:identifier><dc:identifier>https://doi.org/10.1016/j.anl.2026.05.012</dc:identifier><dc:identifier>0385-8146</dc:identifier><dc:language>en</dc:language><dc:relation>Auris Nasus Larynx</dc:relation><dc:rights>info:eu-repo/semantics/openAccess</dc:rights><dc:type>info:eu-repo/semantics/article</dc:type><dc:identifier>https://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/10458</dc:identifier></oai_dc:dc></metadata></record></GetRecord></OAI-PMH>